Form 4 for ALXO ALX ONCOLOGY HOLDINGS INC
Accepted 2026-08-18 17:51:24 ET · period of report 2026-08-17 · accession 0001193125-26-355764 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 17:51 | 2026-08-17 | ALXO | Lettmann Jason | CEO, Dir | S - Sale | $1.93 | -2,230 | 294.4K | -0.8% | -$4,304 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | S | D | 2,230 | $1.93 | 294,379 | D | — | — | (F1) The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. (F2) Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026. |